Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders (RIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01050855
Recruitment Status : Recruiting
First Posted : January 18, 2010
Last Update Posted : February 18, 2020
Sponsor:
Information provided by (Responsible Party):
Children's Hospital of Philadelphia

Brief Summary:

This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source.

Recently, reduced intensity conditioning (RIC) regimens have been used for both adult patients with leukemias and pediatric patients with non-malignant diseases. These regimens are better tolerated, resulting in less transplant related morbidity and mortality. Stable mixed chimerism, while insufficient for eradication of leukemias, may be sufficient to cure patients with non-malignant diseases.


Condition or disease Intervention/treatment Phase
Non Malignant Diseases Immunodeficiencies Hemoglobinopathies Drug: RIC: Distal Campath Drug: RIC:Intermediate Campath Drug: RIC: Mini Busulfan Phase 2

Detailed Description:

There are two conditioning regimens in this protocol for children >6 months. Alemtuzumab (Campath), Fludarabine and Melphalan are used. The regimens differ by the timing and dosing of Alemtuzumab (Campath). The two timings are distal and intermediate.

  • Distal campath is initiated 22 days prior to the allogeneic transplant.
  • Intermediate campath is initiated 14 days prior to allogeneic transplant.

The conditioning regimen for children with immunodeficiencies <6 months omits melphalan, and substitutes two days of busulfan. This regimen is successfully used in the UK, and has been successful in a 3 month old infant at CHOP who engrafted with a haploidentical donor.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
Study Start Date : January 2008
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RIC: Distal Campath

Day Treatment

Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) over 2 hours

Day - 21 to-19 Alemtuzumab IV/ SQ

Day - 7 to -3 Readmission to hospital Fludarabine IV

Day - 2 Melphalan IV

Day - 1 Begin cyclosporine infusion

Day 0 Transplant: Bone marrow or cord blood infusion

Drug: RIC: Distal Campath
Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Other Name: Reduced Intensity Conditioning Regimen

Experimental: RIC:Intermediate Campath

Day Treatment

Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)

Day - 7 to -3 Fludarabine IV

Day - 2 Melphalan 140 mg/m2 IV

Day - 1 Cyclosporine infusion starts

Day 0 Transplant: Bone marrow or cord blood infusion

Drug: RIC:Intermediate Campath
Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Other Name: Reduced Intensity Conditioning Regimen

Experimental: RIC: Mini Busulfan

Day Treatment

Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)

Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)

Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV

Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV

Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV

Day - 3 Fludarabine IV

Day - 2 Fludarabine IV Cyclosporine infusion

Day - 1 Rest

Day 0 Transplant: Bone marrow or cord blood infusion

Drug: RIC: Mini Busulfan
Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
Other Name: Reduced Intensity Conditioning Regimen




Primary Outcome Measures :
  1. Engraftment and Survival [ Time Frame: Post Transplant -100 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >6 months- 25 years
  2. Diseases eligible for Distal Alemtuzumab:

    • Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome
    • Sickle cell disease
    • Thalassemia major
    • Bone marrow failure
  3. Diseases eligible for Intermediate Alemtuzumab

    • Hemophagocytic lymphohistiocytosis other macrophage activation syndromes, severe Langerhans histiocytosis
    • Severe combined immune deficiency, adenosine deaminase deficiency, common variable immunodeficiency
    • Wiskott-Aldrich syndrome
  4. Organ criteria:

    • Cardiac: Echocardiogram shortening fraction >27%
    • Renal: Serum creatinine less than 1.5 times the upper limit of normal for age
    • Hepatic: liver function tests must be less than 5 times the upper limit of normal
  5. No active infections

Exclusion criteria

1. Uncontrolled bacterial, fungal or viral infections


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01050855


Contacts
Layout table for location contacts
Contact: Barbara McGlynn 215-590-1303 mcglynn@email.chop.edu
Contact: Patricia Hankins, RN 215-590-5168 hankinsp@email.chop.edu

Locations
Layout table for location information
United States, Pennsylvania
The Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Barbara McGlynn    215-590-1303    mcglynn@email.chop.edu   
Contact: Patricia Hankins, RN    215 590-5168    hankinsp@email.chop.edu   
Principal Investigator: Nancy J Bunin, MD         
Sponsors and Collaborators
Children's Hospital of Philadelphia
Investigators
Layout table for investigator information
Principal Investigator: Nancy J Bunin, MD Children's Hospital of Philadelphia
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT01050855    
Other Study ID Numbers: 08-005658
CHP 894 ( Other Identifier: Children's Hospital of Philadelphia )
First Posted: January 18, 2010    Key Record Dates
Last Update Posted: February 18, 2020
Last Verified: February 2020
Keywords provided by Children's Hospital of Philadelphia:
Non-malignant diseases
Immune deficiencies
Hemoglobinopathies
Reduced Intensity Conditioning(RIC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinopathies
Hematologic Diseases
Genetic Diseases, Inborn
Busulfan
Alemtuzumab
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological